Immunocore GmbH is a commercial-stage biotechnology company that develops and commercializes T cell receptor (TCR)-based immunotherapies. Using its proprietary ImmTAX platform, the company develops bispecific TCR therapies for oncology, infectious diseases and autoimmune conditions and maintains a pipeline of clinical and preclinical programs, including the approved therapy KIMMTRAK (tebentafusp) for certain uveal melanoma patients.
AI-generated
Offering
Products & services
Industry:Pharmaceutical Industry
✓ Offered5
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Immunomodulatory medicines for cancer, infectious diseases and autoimmune diseases, developed on the proprietary ImmTAX platform; includes approved and in-development therapies.
KIMMTRAK
Approved medicinal product Tebentafusp for the treatment of advanced melanoma; listed on the website for the USA, the United Kingdom, Europe and Switzerland with product information.
Clinical studies
Recruiting clinical studies for new therapies, including Tebentafusp, IMC-F106C, IMC-P115C, IMC-R117C and IMC-M113V2, with information for patients and healthcare professionals.
Medical information
Requests for information for medical professionals as well as country-specific information pages for the USA and the United Kingdom; additionally, form for medical enquiries.
Externally-sponsored research portal
Submission portal for research projects initiated externally and planned by third parties, which Immunocore accepts as externally sponsored research.
Knowledge
No knowledge articles yet
Once Immunocore GmbH has claimed this profile, we'll publish editorial articles and case studies here together.